Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

This publication has 38 references indexed in Scilit:

• The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102 as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial
  PLOS ONE, 2009
• Humoral and cell‐mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso
  Parasite Immunology, 2009
• Malaria vaccines and their potential role in the elimination of malaria
  Malaria Journal, 2008
• Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
  New England Journal of Medicine, 2008
• Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
  New England Journal of Medicine, 2008
• Peptide based malaria vaccine development: personal considerations
  Microbes and Infection, 2007
• Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa
  Vaccine, 2007
• A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
  PLoS Clinical Trials, 2006
• A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge
  Infection and Immunity, 2006
• A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults
  PLoS Medicine, 2004